List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

A pet owner argues against the restriction of Methimazole for in-clinic use, stating that it causes treatment delays and reduces patient compliance. They highlight that liquid and transdermal forms are easier for owners to administer than tablets and that the new regulations do not serve the best interests of cats.

A veterinary professional expresses frustration over the current difficulty in purchasing Methimazole for office stock. They argue that having the medication on hand is necessary to provide immediate treatment for hyperthyroid cats and to prevent gaps in medication for existing patients.

The commenter, likely a veterinary professional or pet owner, advocates for the inclusion of transdermal methimazole on the list of bulk drug substances for compounding. They argue that it is an essential medication for the long-term management of feline hyperthyroidism, particularly for cats that cannot tolerate oral medications.

A veterinary clinic owner (business) argues against the restriction of Methimazole from office stock. They state that the restriction delays treatment for sick cats who cannot tolerate oral medication, and they request that the FDA reconsider the decision.

A pet owner is requesting that Methimazole be included as a compounded transdermal option for cats. They argue that this would be a significant benefit for pet owners who have difficulty administering oral pills to hyperthyroid cats.

A veterinary professional (implied by the mention of "patients" and "owners") argues in favor of including methimazole on the list of bulk drug substances for compounding. They state that the current delay in obtaining compounded medications leaves pets untreated for significant periods, creating a need for easier access to compounded options.

The commenter, identifying as a group of veterinarians, argues that the proposed action is necessary to provide timely treatment for sick animals. They highlight the need for faster access to medications like Methimazole liquid and transdermal forms, which are difficult for some pet owners to administer in pill form.

A veterinary practitioner who treats felines argues in favor of including methimazole on the list of bulk drug substances for compounding. They state that having compounded transdermal forms in stock is essential for treating hyperthyroidism and ensuring patients can receive regular medication.

A veterinary professional (implied by the mention of "our feline patients") argues in favor of including methimazole in the list of bulk drug substances for compounding. They state that compounded transdermal formulations are essential for treating hyperthyroidism in cats that cannot easily take oral pills.

A veterinary practice representative argues that the new restrictions on bulk drug substances have created significant administrative burdens and logistical difficulties for their clinic. They express concern over delays in receiving medications for patients and the loss of convenient delivery options like transdermal pens.